CAS 1030377-33-3

Suvorexant

Description:

Suvorexant is a medication primarily used for the treatment of insomnia, particularly in individuals who have difficulty falling asleep or staying asleep. It functions as an orexin receptor antagonist, specifically targeting the OX1 and OX2 receptors, which play a crucial role in regulating the sleep-wake cycle. By inhibiting these receptors, Suvorexant promotes sleep onset and maintenance. The substance is typically administered orally and has a relatively long half-life, which can influence its dosing schedule. In terms of its chemical characteristics, Suvorexant has a molecular formula that reflects its complex structure, which includes multiple functional groups contributing to its pharmacological activity. It is classified as a small organic molecule and is generally well-tolerated, although it may cause side effects such as drowsiness, dizziness, or headache. As with any medication, it is essential for users to consult healthcare professionals regarding its use, potential interactions, and contraindications.

Formula: C₂₃H₂₃ClN₆O₂

InChI: InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1

InChI key: InChIKey=JYTNQNCOQXFQPK-MRXNPFEDSA-N

SMILES: C(=O)(C1=C(C=CC(C)=C1)N2N=CC=N2)N3CCN(CC[C@H]3C)C4=NC=5C(O4)=CC=C(Cl)C5

Synonyms:

• 5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole
• Belsomra
• Methanone, [(7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]-
• Mk-4305
• [(7R)-4-(5-Chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
• [(R)-4-(5-Chloro-benzooxazol-2-yl)-7-methyl-[1,4]diazepan-1-yl]-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-methanone
• Suvorexant

Suvorexant

Controlled Product

CAS: 1030377-33-3

Applications Suvorexant (MK-4305) is a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation. References Cox, C., et al.: J. Med. Chem., 53, 5320 (2010); Baxter, C., et al.: Org. Process Res. Dev., 15, 367 (2011); Winrow, C., et al.: J. Neurogenet., 25, 52 (2011); Mieda, M., et al.: CNS Drugs, 27, 83 (2013); Osborne, R.: Nat. Rev. Drug Discov., 12, 492 (2013)

Formula: C₂₃H₂₃ClN₆O₂

Color and Shape: Neat

Molecular weight: 450.92

Ref: TR-S870000

Suvorexant

Controlled Product

CAS: 1030377-33-3

Color and Shape: Neat

Ref: 86-MM3792.00

Suvorexant-d6

Controlled Product

CAS: 1030377-33-3

Applications Suvorexant-d6 is the labeled analog of Suvorexant (S870000), a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation. References Cox, C., et al.: J. Med. Chem., 53, 5320 (2010); Baxter, C., et al.: Org. Process Res. Dev., 15, 367 (2011); Winrow, C., et al.: J. Neurogenet., 25, 52 (2011); Mieda, M., et al.: CNS Drugs, 27, 83 (2013); Osborne, R.: Nat. Rev. Drug Discov., 12, 492 (2013)

Formula: C₂₃H₁₇D₆ClN₆O₂

Color and Shape: Neat

Molecular weight: 456.96

Ref: TR-S870002

Suvorexant-d6

CAS: 1030377-33-3

Formula: C₂₃H₁₇D₆ClN₆O₂

Molecular weight: 456.96

Ref: 4Z-S-120002

Suvorexant

CAS: 1030377-33-3

Formula: C₂₃H₂₃ClN₆O₂

Color and Shape: White To Off-White Solid

Molecular weight: 450.93

Ref: 4Z-S-120001

Suvorexant

Controlled Product

CAS: 1030377-33-3

Dual orexin receptor antagonist

Formula: C₂₃H₂₃ClN₆O₂

Purity: Min. 98 Area-%

Color and Shape: White Powder

Molecular weight: 450.92 g/mol

Ref: 3D-FS65089